Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Current Deferred Revenue (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Current Deferred Revenue for 8 consecutive years, with $194000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Current Deferred Revenue fell 84.91% to $194000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $194000.0, a 84.91% decrease, with the full-year FY2025 number at $194000.0, down 84.91% from a year prior.
  • Current Deferred Revenue was $194000.0 for Q4 2025 at Rhythm Pharmaceuticals, down from $1.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $9.4 million in Q1 2022 to a low of $194000.0 in Q4 2025.
  • A 5-year average of $2.3 million and a median of $1.3 million in 2023 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: changed 0.0% in 2024, then crashed 84.91% in 2025.
  • Rhythm Pharmaceuticals' Current Deferred Revenue stood at $7.0 million in 2021, then crashed by 79.51% to $1.4 million in 2022, then dropped by 10.32% to $1.3 million in 2023, then changed by 0.0% to $1.3 million in 2024, then plummeted by 84.91% to $194000.0 in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Current Deferred Revenue are $194000.0 (Q4 2025), $1.3 million (Q4 2024), and $1.3 million (Q3 2024).